Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma
- Authors
- Park, Yong; Choi, Yoon Ji; Park, Se Jong; Lee, Se Ryeon; Sung, Hwa Jung; Park, Kyong Hwa; Kim, Soek Jin; Choi, Chul Won; Jung, Kwang Yoon; Kim, Byung Soo
- Issue Date
- 2011
- Publisher
- KARGER
- Keywords
- Diffuse large B cell lymphoma; Granulysin; Chemotherapy
- Citation
- ACTA HAEMATOLOGICA, v.126, no.2, pp 79 - 86
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- ACTA HAEMATOLOGICA
- Volume
- 126
- Number
- 2
- Start Page
- 79
- End Page
- 86
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/14162
- DOI
- 10.1159/000327255
- ISSN
- 0001-5792
1421-9662
- Abstract
- Aim: Granulysin (cytolytic molecules of cytotoxic T lymphocytes and natural killer cells) is synthesized as cytosolic 9-kDa and secretary 15-kDa isoforms. We evaluated the prognostic significance of the pretreatment serum level of 15-kDa granulysin in patients with diffuse large B cell lymphoma (DLBCL). Patients and Methods: A retrospective analysis was conducted on 88 DLBCL patients treated homogeneously with standard chemotherapy. The granulysin level was quantified in pretreatment samples. Results: The granulysin level in DLBCL patients was significantly lower than that in healthy controls (522 +/- 496 vs. 1,945 +/- 1,696 pg/ml; p < 0.0001), and the level in patients who experienced recurrence within 3 years was significantly lower than that of patients without recurrence (305 +/- 337 vs. 720 +/- 607 pg/ml; p = 0.001). Patients with granulysin levels higher than the median level showed significantly longer progression-free and overall survival according to univariate analysis (p = 0.031 and p = 0.014, respectively). In multivariate analysis, the granulysin level was an independently significant prognostic factor of overall survival (p = 0.018; hazard ratio, 0.521; 95% confidence interval, 0.188-0.841). Conclusions: Pretreatment serum level of 15-kDa granulysin may be a valuable prognostic marker in DLBCL patients treated with standard chemotherapy. Copyright (C) 2011 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Otorhinolaryngology-Head and Neck Surgery > 1. Journal Articles
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.